XTalks

MARCH 22, 2023

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. In that time, we’ve gone from running 25 webinars each year to over 400, working with more than 800 expert speakers each year.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Joanna Carlish, managing director, financial services, Tag Americas. Virtual connections.

Regulation 83

Regulation Marketing Sales Branding 83

Drug Discovery World

JANUARY 10, 2023

Pillar 5: Protein OE/Epitope Tags. Our robust monoclonal antibody generation platform delivers large, diverse clone sets, enabling our partners to find fit-for-purpose monoclonal antibodies to suit their applications for 90% of projects. Pillar 4: Biological Characteristics. Small molecules .

Antibody 52

Antibody Protein Reagent Scientist 52

pharmaphorum

DECEMBER 2, 2020

The company’s first product, a palatable anti-parasitic drug, made to taste like toffee, united Pfizer’s skills as a chemist with Erhart’s training as a confectioner. The “first industrial war” involved drug producers as much as weapons manufacturers. It was a success, and set the pattern for the company’s future development.

Sales 127

Sales Production Drugs Marketing 127

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). Given the complexity of Alzheimer’s on a disease and societal level, we anticipate the need for several treatment options to meet the multiple and diverse needs of all people living with Alzheimer’s and their caregivers.

Antibody 52

Antibody In-Vitro Trials Development 52

XTalks

AUGUST 17, 2020

Immune checkpoint inhibitors : these are drugs that block immune checkpoints, allowing immune cells to elicit enhanced responses to cancer cells. IL-2 is not only a validated T cell target, but is also an approved drug for metastatic melanoma and renal cell carcinoma. chimeric receptor antigen [CAR] T cell) immune modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Roots Analysis

AUGUST 28, 2022

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. For more details on this emerging domain, check out the following report : SPATIAL GENOMICS MARKET. Web: [link].

Genome 52

Genome Genomics RNA Genome Project 52

Drug Discovery World

NOVEMBER 13, 2023

Noel Pauli, PhD, Group Leader, Antibody Engineering, Adimab, on: ‘Harnessing in vivo diversities with a yeast-based platform for the discovery of antibodies against multi-pass membrane proteins’. Oliver Hartley, PhD, Vice President, Drug Discovery, Orion Biotechnology, on: ‘Targeting small protein GPCRs by engineering their natural ligands’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

The first three include: Sungjin Park, PhD, CEO, Onegene Biotechnology, on: ‘UniStac: Enzyme-mediated conjugation technology for accelerated development of tetraspecific NASH drug’. Ioanna Stamati, PhD, Team Leader, Bioconjugation, Antikor Biopharma, on: ‘Antibody fragment drug-conjugates (FDCs): Analysing novel formats with high DAR’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

OCTOBER 21, 2022

The main principle involves a well-defined light source such as that produced by lasers that excites fluorescent tags bound to the cells or particles present in a sample. The post Leveraging flow cytometry in drug discovery appeared first on Drug Discovery World (DDW). Future directions . Volume 23 – Issue 4, Fall 2022.

Reagent 52

Reagent Antibody Drugs Protein 52

The Pharma Data

MAY 4, 2021

Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for Lorbrena, expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Lorbrena (lorlatinib) — In March 2021, Pfizer announced that the U.S.

Vaccination 40

Vaccination Vaccine Production Sales 40